Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Vitamin D Dose Finding Study

This study has been completed.
National Institutes of Health (NIH)
National Center for Complementary and Integrative Health (NCCIH)
Information provided by (Responsible Party):
Children's Hospital of Philadelphia Identifier:
First received: March 23, 2010
Last updated: August 1, 2013
Last verified: August 2013
Results First Received: January 7, 2013  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety Study;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Conditions: HIV Infections
Intervention: Drug: Cholecalciferol (Vit D3)

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
The Study started enrollment in 01/2010 and completed in 01/2011. A total of 44 subjects were enrolled including 19 with perinatally-acquired HIV/AIDS (PA) and 25 with behaviorally-acquired HIV/AIDS (BA).

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Subjects taking a vitamin D supplement or multi-vitamin were eligible if they were willing to discontinue supplementation after a minimum of a 2 month washout period.

Reporting Groups
4000IU/d of Vitamin D3 No text entered.
7000IU/d Vitamin D3 No text entered.

Participant Flow:   Overall Study
    4000IU/d of Vitamin D3   7000IU/d Vitamin D3
STARTED   22   22 
COMPLETED   21   21 

  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
4000IU/d of Vitamin D3 No text entered.
7000IU/d Vitamin D3 No text entered.
Total Total of all reporting groups

Baseline Measures
    4000IU/d of Vitamin D3   7000IU/d Vitamin D3   Total
Overall Participants 
[units: participants]
 22   22   44 
[units: participants]
<=18 years   9   7   16 
Between 18 and 65 years   13   15   28 
>=65 years   0   0   0 
[units: years]
Mean (Standard Deviation)
 18.4  (4.5)   19.1  (5.0)   18.7  (4.7) 
[units: participants]
Female   7   7   14 
Male   15   15   30 
Region of Enrollment 
[units: participants]
United States   22   22   44 

  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Safety   [ Time Frame: 12 weeks ]

2.  Primary:   Efficacy of the Two Doses (4000 and 7000 IU/d)   [ Time Frame: 12 weeks ]

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats

  More Information